Michael B. Atkins, M.D. is the deputy director of the Georgetown Lombardi Comprehensive Cancer Center.
He serves on the advisory boards of the Melanoma Foundation of New England, the Melanoma Research Foundation Breakthrough Consortium and the Kidney Cancer Association. He is a founding member and long time co-leader of the Cytokine Working Group and is past president of the International Society for Biological Therapy of Cancer.
Dr. Atkins is a translational investigator whose major research interests are immunotherapy of malignancy, with specific emphasis on the use of cytokines and understanding and overcoming cancer associated immune suppression, novel treatments of melanoma and renal cell carcinoma, predictive markers for response to biologic therapy, and anti-angiogenic and targeted therapies. He played a key role in the clinical development of IL-2 from the early Phase I trials to its eventual approval by the FDA for treatment of metastatic renal cell carcinoma and melanoma and is currently investigating the potential utility of CTLA4 and the PD1 pathway antibodies, mechanisms of enhancing sensitivity of melanoma to selective raf pathway inhibitors, mechanisms of RCC resistance to VEGF targeted therapies, and opportunities for selecting patients for particular treatments based on tumor and immune based parameters.